Pulmonary, Critical Care and Sleep Medicine Division, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York.
Respir Care. 2023 Sep;68(9):1213-1220. doi: 10.4187/respcare.10643. Epub 2023 May 30.
To understand the fate of aerosols delivered by high-flow nasal cannula using continuous nebulization, an open-source anatomical model was developed and validated with a modified real-time gamma ratemeter technique. Mass balance defined circuit losses. Responsiveness to infusion rate and device technology were tested.
A nasal airway cast derived from a computed tomography scan was converted to a 3-dimensional-printed head and face structure connected to a piston ventilator (breathing frequency 30 breaths/min, tidal volume 750 mL, duty cycle 0.50). For mass balance experiments, saline mixed with Technetium-99m was infused for 1 h. Aerosol delivery was measured using a gamma ratemeter oriented to an inhaled mass filter at the hypopharynx of the model. Background and dead-space effects were minimized. All components were imaged by scintigraphy. Continuous nebulization was tested at infusion rates of 10-40 mL/h with gas flow of 60 L/min using a breath-enhanced jet nebulizer (BEJN), and a vibrating mesh nebulizer. Drug delivery rates were defined by the slope of ratemeter counts/min (CPM/min) versus time (min).
The major source of aerosol loss was at the nasal interface (∼25%). Significant differences in deposition on circuit components were seen between nebulizers. The nebulizer residual was higher for BEJN ( = .006), and circuit losses, including the humidifier, were higher for vibrating mesh nebulizer ( = .006). There were no differences in delivery to the filter and head model. For 60 L/min gas flow, as infusion pump flow was increased, the rate of aerosol delivery (CPM/min) increased, for BEJN from 338 to 8,111; for vibrating mesh nebulizer, maximum delivery was 2,828.
The model defined sites of aerosol losses during continuous nebulization and provided a realistic in vitro system for testing aerosol delivery during continuous nebulization. Real-time analysis can quantify effects of multiple changes in variables (nebulizer technology, infusion rate, gas flow, and ventilation) during a given experiment.
为了了解高流量鼻导管输送的气溶胶在持续雾化时的命运,我们开发了一个开源解剖模型,并使用改良的实时γ射线率计技术对其进行了验证。质量平衡定义了回路损耗。测试了对输注率和设备技术的响应。
从计算机断层扫描中获得的鼻气道模型被转换为 3 维打印的头部和面部结构,连接到活塞呼吸机(呼吸频率 30 次/分钟,潮气量 750 毫升,占空比 0.50)。为了进行质量平衡实验,将含有 Technetium-99m 的生理盐水输注 1 小时。使用面向模型下咽的γ射线率计测量气溶胶输送。背景和死腔效应最小化。所有组件均通过闪烁照相进行成像。使用呼吸增强射流雾化器(BEJN)和振动网孔雾化器,在 60 L/min 的气体流量下,以 10-40 mL/h 的输注率测试持续雾化。药物输送率由每分钟(CPM/min)与时间(min)的射线率计计数斜率定义。
气溶胶损失的主要来源是在鼻接口处(约 25%)。不同雾化器在回路组件上的沉积存在显著差异。BEJN 的雾化器残留量较高( =.006),振动网孔雾化器的回路损失(包括加湿器)较高( =.006)。对过滤器和头部模型的输送没有差异。对于 60 L/min 的气体流量,随着输注泵流量的增加,气溶胶输送率(CPM/min)增加,BEJN 从 338 增加到 8,111;对于振动网孔雾化器,最大输送量为 2,828。
该模型定义了连续雾化时气溶胶损失的部位,并为连续雾化时气溶胶输送的测试提供了一个现实的体外系统。实时分析可以定量分析在给定实验中多种变量(雾化器技术、输注率、气体流量和通气)变化的影响。